Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q42004227

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Clinical use and applications of histone deacetylase inhibitors in multiple myeloma DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Innovative agents in multiple myeloma Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.An update on the use of lenalidomide for the treatment of multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.Promising therapies in multiple myeloma.The biological significance of histone modifiers in multiple myeloma: clinical applications

P2860

Q26740359-BB34C210-0789-48D4-82BD-6F0ED1D16C2B Q26745930-36730E04-6A47-40BC-AC40-F9D5B87155E9 Q26749421-52FB9B4C-9B10-48D1-9C50-4AA23E3D4BA2 Q27022493-6D422DC9-32CB-4479-B4CE-4944A7A99AA0 Q27026478-D38F3706-2E8F-4E4B-9F19-5C6B89CF79F4 Q33423168-EE09F536-2BAB-451A-9246-B58D5876B655 Q33436890-6D5B6B84-5E7D-4C24-A17D-BA1C2B2568D0 Q33658023-6A8F9D74-FDFC-40EB-90E6-39443084B1D7 Q35726371-D83756DE-23F5-40C9-8450-95B6F0831D4B Q36145310-49B07819-C3CD-440A-97C8-028A212D67FE Q37199772-6C38766C-D0DF-4C60-9426-76ACB647F93C Q38255333-45375BBE-F459-441E-8435-5CBF9C9A21DE Q38545607-C72AA0FF-5F93-4165-A8C4-2FA7C13079DD Q38630472-3EDA5CC8-25C3-4B15-95CC-205D509BE91D Q38813504-1793D605-B65D-4726-A185-202B55456F58 Q39234159-C06BE1BF-D562-4780-9562-751C4F17D2EE Q41316676-556D20ED-C8B5-488E-A132-FFE075EE807E Q42581682-249D48CF-791D-4EAF-B9AA-15071D82D492 Q58718492-752F681A-C885-496C-B3CB-689341A1D8D0

P2860

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q42004227

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Vorinostat in combination with ...... r refractory multiple myeloma.

@en

type

label

Vorinostat in combination with ...... r refractory multiple myeloma.

@en

prefLabel

Vorinostat in combination with ...... r refractory multiple myeloma.

@en

P1433

Q42004227-FA783994-EB0A-4D4B-95E7-4E3584248B0D

P1476

Q42004227-7C4D74D3-384D-46C1-8B94-1C7723D3458B

P2093

Q42004227-212EC10C-567A-4ED5-9A24-50A2B742D93B

Q42004227-3D8FAC5B-BC08-4588-9BF3-8B6786177C94

Q42004227-4D9E101B-E9C9-4182-A104-E8F884FB0851

Q42004227-5658A3FA-5002-4875-938F-EBF3AA0FE33C

Q42004227-87CE86B9-A09C-46FB-8398-FD403ABAA3AF

Q42004227-CF9E5350-1A12-47C0-BF76-BDC092F20FC5

Q42004227-E7D12F7C-0BB0-45F3-9EC7-9483F8C80B9C

Q42004227-E90BF2CD-7DED-46BA-8A8D-F16AD79D52DC

Q42004227-F58306B4-8E63-40F9-ABB2-ACC23A917C08

Q42004227-F9B9F683-F323-41DF-A7C2-BBF0B2504848

P2860

Q42004227-0050FD76-89ED-407C-B811-F3AE5E5B9CC6

Q42004227-0F402A27-0A6B-4203-B7AE-6EB0F199C0FC

Q42004227-19E01760-F74D-463A-B2B9-8A475B880EAC

Q42004227-1B81FBFD-158E-4F25-A39D-DB5CE74AFEE6

Q42004227-36BA5F1B-74DE-4F80-8A9A-350B83C9EFA1

Q42004227-38AEFB30-632C-4B25-A20D-8824E881AF95

Q42004227-47FD4DBC-8AE3-47CD-8A5A-1EAF9F68BD1F

Q42004227-52C311BE-37D3-42C8-BB09-5D3031737904

Q42004227-5ACE4288-CF30-4E04-AE1A-F2EB43CF455A

Q42004227-65F75713-93B7-4710-A61D-5D3E614E2FA2

P2888

Q42004227-8903C280-FFF3-49AC-9341-6D1BB1B19E2F

P304

Q42004227-86BBC99D-7DD7-4F08-BAF8-59E12C04A5EE

P31

Q42004227-5FB90872-0F41-4D11-9870-AFCA10B54C7C

P356

Q42004227-62541751-6B0D-43A1-BBD1-72141F6B6889

P478

Q42004227-BEF21C78-9D32-4BC0-A8AA-B230C03AAE16

P50

Q42004227-9C01CE9B-7C82-42B1-9335-296C7A7C7DC6

Q42004227-F34D7544-BDCA-4316-A48E-DF4428AF2327

P577

Q42004227-C37DEDB3-C372-4C94-A50B-8C1DECF4FD4D

P5875

Q42004227-B7BC4D4A-C96B-4814-A808-CBDB383C4227

P6179

Q42004227-EE6DE718-8327-4ED3-BD08-A60727A1AF58

P698

Q42004227-48308DA0-93BB-406A-A64F-2380D7DC87D4

P921

Q42004227-7E40446B-A85A-4091-A18A-27D72E7D5668

P932

Q42004227-739053AA-9B66-44F8-805C-68E7E6B702E8

P356

P1433

Blood Cancer Journal

P1476

Vorinostat in combination with ...... or refractory multiple myeloma

@en

P2093

C Gause

http://www.w3.org/2001/XMLSchema#string

C Mitsiades

http://www.w3.org/2001/XMLSchema#string

D Weber

http://www.w3.org/2001/XMLSchema#string

J Eid

http://www.w3.org/2001/XMLSchema#string

J Houp

http://www.w3.org/2001/XMLSchema#string

K C Anderson

http://www.w3.org/2001/XMLSchema#string

P Moreau

http://www.w3.org/2001/XMLSchema#string

P Richardson

http://www.w3.org/2001/XMLSchema#string

S Vuocolo

http://www.w3.org/2001/XMLSchema#string

T Graef

http://www.w3.org/2001/XMLSchema#string

P2860

Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Vorinostat in solid and hematologic malignancies

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

P2888

P304

e182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2014.1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P577

2014-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260375100

http://www.w3.org/2001/XMLSchema#string

P6179

1039469219

http://www.w3.org/2001/XMLSchema#string

P698

24562384

http://www.w3.org/2001/XMLSchema#string

P921

P932

3944659

http://www.w3.org/2001/XMLSchema#string